Navigation Links
Good news for some hard-to-treat hepatitis C patients
Date:6/16/2009

ST. LOUIS In a multi-center trial led by a Saint Louis University researcher, investigators found that a new combination therapy of daily consensus interferon and ribavirin helps some hepatitis C patients who have not responded to previous treatment. The findings, published in the June issue of Hepatology, offer a new option for hepatitis C patients, and may be effective even for those patients with factors that make their condition difficult to treat.

"This represents an important advance for difficult to treat hepatitis C patients who have failed to respond to traditional therapy," said Bruce Bacon, M.D., director of the division of gastroenterology and hepatology at Saint Louis University School of Medicine and co-director of the Saint Louis University Liver Center .

About 4 million people in the U.S. have been infected with hepatitis C; an estimated 10,000 to 12,000 people die from complications each year in this country. Hepatitis C is caused by a virus, transmitted by contact with blood, and may initially be asymptomatic. For patients who develop chronic hepatitis C infection, inflammation of the liver may develop, leading to fibrosis and cirrhosis (scarring of the liver), as well as other complications including liver cancer and death.

For patients with chronic hepatitis C, the prognosis varies. About half fully recover after an initial course of pegylated interferon and ribavirin anti-viral therapy that may last from six months to a year.

The remaining patients, known as non-responders, may improve but the virus is not eliminated. These patients are at greatest risk for worsening, and subsequent treatments have shown limited effectiveness for this group. In addition, those with genotype 1 (a particular genetic variation of the virus), those with high baseline virus levels, those with advanced liver disease and African American patients are all less likely to respond well to treatment.

The study looked at 515 patients at 44 different sites. Patients were given either one of two doses of daily consensus interferon and ribavirin, or no treatment.

For patients with less severe liver damage who had shown some response to initial treatment, the success rate was above 30 percent. The overall results showed that, for patients who had been unresponsive to initial treatment, consensus interferon and ribavirin worked for about 7 percent of patients given the lower dose and about 11 percent of patients given the higher dose of consensus interferon and ribavirin.

"This study shows that select patients who have failed to respond to prior therapy are candidates for retreatment with consensus interferon and ribavirin," Bacon said.


'/>"/>

Contact: Carrie Bebermeyer
bebermcl@slu.edu
314-398-5279
Saint Louis University
Source:Eurekalert

Related medicine news :

1. Hard-to-Treat Leukemia Cell Subtype Identified
2. Tackling a hard-to-treat childhood cancer by targeting epigenetic changes
3. Tackling Hard-to-treat Childhood Cancer by Targeting Epigenetic Changes
4. Blood-clotting protein modified for people with hard-to-treat hemophilia
5. Relaxation training may improve control of hard-to-treat systolic hypertension
6. Revolutionary New Technique Uses Onyx to Fill Hard-To-Treat Aneurysms
7. Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)
8. Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
9. NEJM study points to new era in hepatitis C treatment
10. Resource for Those Living with Hepatitis C Announces Website Redesign
11. AUDIO from Medialink, Bayer Healthcare and Onyx Pharmaceuticals: Facts About Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... , ... Rollon Skin Care Ltd., one of ... the launch of two new skincare products, Prache Antiaging Cream and Prache Antiaging ... surgery or in-patient cosmetic dermatological procedures. , “Prache Antiaging Cream and Prache Antiaging ...
(Date:8/16/2017)... ... August 16, 2017 , ... “Mom, God's Got This: Jamie's Story” is the creation of ... the Lord and has an insatiable appetite for God’s Word. , “I froze between the ... gifts retrieved from packages of oatmeal. I have one to this day on proud display ...
(Date:8/15/2017)... ... , ... The Philadelphia Marathon and the American Association for Cancer Research (AACR) ... City’s commitment to improving the health of its citizens. Dedicated to preventing and curing ... lifestyle as research shows this can help reduce the risk of cancer. ...
(Date:8/15/2017)... ... 15, 2017 , ... IsoComforter, Inc., one of the Nation’s ... new 10x10 bladder pad ( isocomforter.com/product/10x10-sterile-pad/ ). The newly designed bladder pad has ... the patient to enjoy the benefits of cold therapy while resting, sitting, or ...
(Date:8/15/2017)... ... , ... Organizers today announced plans and unveiled the website for Global ... activations held during UN General Assembly week and focused on driving progress toward the ... Week will be held 16-23 September, with events and activations taking place in New ...
Breaking Medicine News(10 mins):
(Date:8/11/2017)... , Aug. 11, 2017 DarioHealth Corp. ... mobile health and big data solutions, today announced that ... Monday, August 14 and host a conference call at ... 2017 operating and financial results and its strategy and ... be hosted by Erez Raphael , Chief Executive ...
(Date:8/7/2017)... , Aug. 7, 2017 Zimmer Biomet Holdings, ... healthcare, today announced that its Board of Directors has approved ... the third quarter of 2017. ... paid on or about October 27, 2017 to stockholders of ... 2017.  Future declarations of dividends are subject to approval of ...
(Date:8/4/2017)... CINCINNATI , Aug. 3, 2017  Agragen, ... science company active in the biopharmaceutical, nutraceutical, and ... its development of its lead drug candidates, AGR131.  ... a proinflammatory cytokine from the blood of patients ... psoriasis, and inflammatory bowel disease. ...
Breaking Medicine Technology: